FDA Recalls Bubble Gum Over Undeclared Colors

Hundreds of pounds of product sold in New Jersey and New York affected by Class II recall

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

The Food and Drug Administration (FDA) has issued a Class II recall for hundreds of pounds of bubble gum sold in New Jersey and New York. The recall was initiated by the manufacturer, Bader Enterprises Inc., because the bubble gum contained undeclared colors, specifically FD&C Blue 1 Lake and FD&C Blue 2 Lake, which were not listed on the product's labeling.

Why it matters

The FDA requires certain ingredients, including color additives, to be properly declared on food labels so consumers can make informed decisions about the products they purchase or consume. When colors are not declared on a product's label, consumers may be unaware of their presence, which is a key part of food safety and regulatory compliance.

The details

The recalled bubble gum was packaged in 2.5‑ounce clear flexible plastic packaging and sold in unit cases totaling 30 pounds. The recall applies to all lots and codes of the product, with a total quantity affected of 400 pounds. The firm voluntarily initiated the recall, and the FDA has classified it as a Class II recall, meaning the use of or exposure to the product may cause temporary or medically reversible adverse health consequences.

  • The recall was initiated on January 16, 2026.
  • The FDA assigned a risk classification on March 3, 2026.

The players

Bader Enterprises Inc.

The recalling firm, located at 115 27th Street, Brooklyn, New York.

Food and Drug Administration (FDA)

The federal agency that classified the recall as a Class II action.

Got photos? Submit your photos here. ›

What’s next

No termination date has been provided for the ongoing recall.

The takeaway

This recall highlights the importance of accurate labeling and transparency for consumers, as the presence of undeclared ingredients can pose potential health risks, even if the probability of serious adverse effects is considered remote.